Enhancement of oral bioavailability of quercetin by metabolic inhibitory nanosuspensions compared to conventional nanosuspensions

Drug Deliv. 2021 Dec;28(1):1226-1236. doi: 10.1080/10717544.2021.1927244.

Abstract

Quercetin-loaded nanosuspensions (Que-NSps) added metabolic inhibitors were evaluated as drug delivery system to promote the oral bioavailability of quercetin. Que-NSps were prepared respectively using d-alpha tocopherol acid polyethylene glycol succinate (TPGS) or Soybean Lecithin (SPC) as stabilizer. On the basis, Piperine (Pip) or sodium oleate (SO) was, respectively, encapsulated in Que-NSps as phase II metabolic inhibitors. The resulting Que-NSps all displayed a mean particle size of about 200 nm and drug loading content was in the range of 22.3-27.8%. The release of quercetin from Que-NSps was slow and sustained. After oral administration of 50 mg/kg different Que-NSps, the levels of free quercetin in plasma were significantly promoted, the concentration of quercetin metabolites (isorhamnetin and quercetin 3-O-β-d-Glucuronide) were decreased. The absolute bioavailability was, respectively 15.55%, 6.93%, 12.38%, and 23.58% for TPGS-Que-NSps, TPGS-SO-Que-NSps, SPC-Que-NSps, and SPC-Pip-Que-NSps, and 3.61% for quercetin water suspension. SPC-Pip-Que-NSps turned out to an ideal nanocarrier combined nano drug delivery system together with metabolic inhibitor to promote oral absorption of quercetin.

Keywords: Quercetin; metabolic inhibition; nanosuspensions; oral bioavailability; pharmacokinetic.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Chemistry, Pharmaceutical
  • Drug Carriers / chemistry
  • Drug Liberation
  • Drug Stability
  • Hydrogen-Ion Concentration
  • Male
  • Nanoparticles / chemistry*
  • Particle Size
  • Quercetin / administration & dosage*
  • Quercetin / analogs & derivatives
  • Quercetin / pharmacokinetics*
  • Rats
  • Rats, Sprague-Dawley
  • Surface Properties
  • Suspensions
  • Xenograft Model Antitumor Assays

Substances

  • Drug Carriers
  • Suspensions
  • 3-methylquercetin
  • Quercetin

Grants and funding

This work was supported by National Natural Science Foundation of China [Grant no. U1401223], CAMS Innovation Fund for Medical Sciences (CIFMS) [Grant no. 2016-I2M-1-012] and Open Fund for State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process [No SKL2020M0203]..